BMS Expands AI Partnership with NVIDIA to Speed Drug Discovery - New Jersey Business & Industry Association
Bristol Myers Squibb (BMS) is expanding its partnership with NVIDIA to use AI in accelerating the drug discovery process. This collaboration will help BMS researchers analyze vast amounts of data and identify potential new treatments more quickly. For small businesses, this highlights the growing importance of AI in life sciences and the potential for partnerships to drive innovation.
What happened
Bristol Myers Squibb is expanding its partnership with NVIDIA to use AI in accelerating the drug discovery process. This collaboration will help researchers analyze vast amounts of data and identify potential new treatments more quickly. By doing so, they can move new treatments from concept to reality faster.
Why it matters
This highlights the growing importance of AI in life sciences and the potential for partnerships to drive innovation. As a business owner in this sector, you may need to consider how AI can help your own operations, whether through partnerships or investing in your own capabilities.
The takeaway
Consider how AI can help your business in life sciences, whether through partnerships or investing in your own capabilities. This could help you drive innovation and stay competitive in your field.
Our plain-English take, written from public reporting for operational business owners. Always read the original for full context.
Nayre builds the AI systems behind stories like this.
Chatbots, workflow automation, finance intelligence, and internal knowledge systems. Built for operational teams, shipped in days.